When a gain of 16p13.3 was present, the prognosis of these patients over all tumour stages was worse than the prognosis for patients without a 16p13.3 alteration or with a loss of the RBFOX1 gene (HR = 5.018, **P = 0.020). The gene discussed is RBFOX1; the disease is neoplasm.